NF-κB Inhibition in Amyotrophic Lateral Sclerosis

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This is a Phase II, single centre, randomized, parallel, double blind, placebo-controlled clinical trial to determine the safety of Withania somnifera in participants with Amyotrophic Lateral Sclerosis (ALS).
Epistemonikos ID: 005a8d178ce0ccf84e2ea7c53aa517411c918d7d
First added on: May 09, 2024